| Level of tau protein in children treated for acute lymphoblastic leukemia. | |
| | |
MedLine Citation:
|
PMID: 16647996 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Long-term neuropsychological complications such as attention and concentration disturbances, poor school performance, hyperexcitability, and even leukoencephalopathy have been described in children after chemotherapy for acute lymphoblastic leukemia. Elevation of the cerebrospinal fluid level of tau protein, associated with neuronal axons, is a neurodegenerative marker. The aim of the study was to assess the level of cerebrospinal fluid tau protein in children with acute lymphoblastic leukemia. The study included 26 patients with acute lymphoblastic leukemia and 19 patients with clinical symptoms of cerebrospinal meningitis (reference group). Tau protein levels were determined by enzyme-linked immunosorbent assay. Cerebrospinal fluid total protein level was not elevated in any of the samples. The examination was performed at diagnosis, after induction treatment, during consolidation, and after reinduction, i.e. before maintenance therapy. Neither age nor sex had an effect on tau protein levels in both groups. The mean tau protein value at diagnosis was 244.84 +/- 98.96 pg/mL in the study group (norm 300 pg/mL) and produced no correlation with initial leukocytosis, lactate dehydrogenase activity, or organomegaly at this point. Dynamic analysis revealed a statistically significant increase in tau protein after induction treatment (431.25 +/- 232.50) as compared with its level at diagnosis (244.84 +/- 98.96, P < 0.008) and later during treatment. The levels of tau protein at various points of treatment did not differ statistically significantly between the groups, except for the values obtained after termination of remission induction. The observed metabolic changes in tau protein, which is a known marker of neuronal damage, indicate that some patients are at a greater risk of central nervous system disorders. This finding requires further studies, also in reference to other central nervous system proteins, and confirms the necessity of long-term follow-up of leukemia patients. |
| | |
Authors:
|
Katarzyna Muszyńska-Rosłan; Maryna Krawczuk-Rybak; Piotr T Protas; Adam Hołownia |
Related Documents
:
|
10968506 - Nitrated proteins in bronchoalveolar lavage fluid of patients at risk of ventilator-ass... 4067316 - The influence of hapten density on the assay of penicilloylated proteins in fluids. 12773106 - Identification and immunohistochemical localization of a haptoglobin-like protein in th... 107466 - Association of tritium-labelled estradiol, progesterone and 17 alpha-hydroxyprogesteron... 8546136 - Abnormal permeability to proteins and glomerular lesions: a meta-analysis of experiment... 3322326 - Isolation and characterization of monoclonal antibodies to proline dehydrogenase from e... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Pediatric neurology Volume: 34 ISSN: 0887-8994 ISO Abbreviation: Pediatr. Neurol. Publication Date: 2006 May |
Date Detail:
|
Created Date: 2006-05-01 Completed Date: 2006-07-06 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8508183 Medline TA: Pediatr Neurol Country: United States |
Other Details:
|
Languages: eng Pagination: 367-71 Citation Subset: IM |
Affiliation:
|
Department of Oncology, Medical University of Białystok, Bialystok, Poland. kmroslan@amb.edu.pl |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Antineoplastic Agents / adverse effects* Biological Markers / cerebrospinal fluid Brain Diseases / cerebrospinal fluid*, chemically induced* Child Child, Preschool Female Humans Infant Leukemia, B-Cell / cerebrospinal fluid, drug therapy Leukemia, T-Cell / cerebrospinal fluid, drug therapy Male Meningitis / cerebrospinal fluid Precursor Cell Lymphoblastic Leukemia-Lymphoma / cerebrospinal fluid, drug therapy* tau Proteins / cerebrospinal fluid* |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Biological Markers; 0/tau Proteins |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Prognostic value of 1H-MRS in neonatal encephalopathy.
Next Document: The incidence of Rett syndrome in France.